Clinicopathological significance of RASSF1A reduced expression and hypermethylation in hepatocellular carcinoma

[1] Orito E(2007)Differences of HBV genotypes and hepatocellular carcinoma in Asian countries Hepatol Res 37 S33-S35

[2] Mizokami M(2008)Therapeutic strategy of advanced hepatocellular carcinoma by using combined intra-arterial chemotherapy Recent Pat Anticancer Drug Discov 3 220-226

[3] Nagai H(2000)Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3 Nat Genet 25 315-319

[4] Sumino Y(2008)RASSF1A protein expression and correlation with clinicopathological parameters in renal cell carcinoma BMC Urol 8 12-2604

[5] Dammann R(2008)Alterations of 3p21.31 tumor suppressor genes in head and neck squamous cell carcinoma: correlation with progression and prognosis Int J Cancer 123 2594-1406

[6] Li C(2008)Quantitative promoter hypermethylation profiles of ductal carcinoma in situ in North American and Korean women: potential applications for diagnosis Cancer Biol Ther 7 1398-699

[7] Yoon JH(2008)Promoter hypermethylation and reduced expression of RASSF1A are frequent molecular alterations of endometrial carcinoma Mod Pathol 21 691-205

[8] Chin PL(2007)Reduced expression of RASSF1A in esophageal and nasopharyngeal carcinomas significantly correlates with tumor stage Cancer Lett 257 199-308

[9] Bates S(2007)Association of diminished expression of RASSF1A with promoter methylation in primary gastric cancer from patients of central China BMC Cancer 7 120-371

[10] Pfeifer GP(2008)Putative association of the single nucleotide polymorphisms in RASSF1A promoter with Korean lung cancer Lung Cancer 61 301-1153

[1] Orito E(2007)Differences of HBV genotypes and hepatocellular carcinoma in Asian countries Hepatol Res 37 S33-S35

[2] Mizokami M(2008)Therapeutic strategy of advanced hepatocellular carcinoma by using combined intra-arterial chemotherapy Recent Pat Anticancer Drug Discov 3 220-226

[3] Nagai H(2000)Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3 Nat Genet 25 315-319

[4] Sumino Y(2008)RASSF1A protein expression and correlation with clinicopathological parameters in renal cell carcinoma BMC Urol 8 12-2604

[5] Dammann R(2008)Alterations of 3p21.31 tumor suppressor genes in head and neck squamous cell carcinoma: correlation with progression and prognosis Int J Cancer 123 2594-1406

[6] Li C(2008)Quantitative promoter hypermethylation profiles of ductal carcinoma in situ in North American and Korean women: potential applications for diagnosis Cancer Biol Ther 7 1398-699

[7] Yoon JH(2008)Promoter hypermethylation and reduced expression of RASSF1A are frequent molecular alterations of endometrial carcinoma Mod Pathol 21 691-205

[8] Chin PL(2007)Reduced expression of RASSF1A in esophageal and nasopharyngeal carcinomas significantly correlates with tumor stage Cancer Lett 257 199-308

[9] Bates S(2007)Association of diminished expression of RASSF1A with promoter methylation in primary gastric cancer from patients of central China BMC Cancer 7 120-371

[10] Pfeifer GP(2008)Putative association of the single nucleotide polymorphisms in RASSF1A promoter with Korean lung cancer Lung Cancer 61 301-1153